stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Book value per share
Roivant Sciences Ltd.'s book value per share at the end of fiscal 2026 was 7.6×, up 6.66% from 7.2× in fiscal 2025. At the end of the quarter to 30 June 2026 it was 6.8×. Over the past ten years it has ranged from 2.3× (fiscal 2023) to 8.2× (fiscal 2024); the current reading is higher than 71% of that period. Roivant Sciences Ltd. ranks 117th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2026 | 7.6× | 6.66% |
| FY2025 | 7.2× | (13.14%) |
| FY2024 | 8.2× | 265.06% |
| FY2023 | 2.3× | (25.92%) |
| FY2022 | 3.0× | (5.96%) |
| FY2021 | 3.2× | (58.23%) |
| FY2020 | 7.7× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 6.8× | (9.41%) |
| Mar 2026 | 7.5× | 5.60% |
| Dec 2025 | 7.1× | 1.15% |
| Sep 2025 | 7.1× | (0.31%) |
| 21 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| INCY Incyte Corporation compare | 27.8× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 26.9× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| RVMD Revolution Medicines, Inc. compare | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement